Ownership and insider activity for Progyny, Inc. (PGNY): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists.
Price
| Price | $25.86 |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-23 | Swartz Allison | S-Sale | 3,903 | $102K |
| 2026-09-17 | Clapp Geoffrey | F-InKind | 819 | $22K |
| 2026-09-10 | GORDON KEVIN K | S-Sale | 11,500 | $312K |
| 2026-09-10 | GORDON KEVIN K | M-Exempt | 22,000 | $286K |
| 2026-09-10 | GORDON KEVIN K | M-Exempt | 22,000 | $286K |
| 2026-09-10 | GORDON KEVIN K | F-InKind | 10,500 | $286K |
| 2026-09-10 | GORDON KEVIN K | S-Sale | 11,500 | $321K |
| 2026-09-03 | Anevski Peter | F-InKind | 5,361 | $141K |
| 2026-09-03 | Swartz Allison | F-InKind | 828 | $22K |
| 2026-09-04 | Swartz Allison | F-InKind | 479 | $13K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.7M | $127,000 | $80.4M | $70.3M | $91.4M | $120.1M | $97.3M | $162.3M | $112.2M |
| Short-term Investments | 0 | 0 | 0 | $39.0M | $28.0M | $69.2M | $273.8M | $65.6M | $197.9M |
| Receivables | $11.4M | $23.3M | $47.1M | $75.7M | $134.6M | $240.1M | $241.9M | $235.3M | $220.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $16.8M | $24.5M | $132.4M | $190.2M | $258.5M | $433.9M | $640.4M | $472.7M | $551.8M |
| Property, Plant & Equipment | $597,000 | $776,000 | $3.1M | $12.1M | $12.8M | $15.3M | $27.8M | $29.6M | $54.9M |
| Goodwill | $11.9M | $11.9M | $11.9M | $11.9M | $11.9M | $11.9M | $11.9M | $15.5M | $20.0M |
| Intangible Assets | $5.3M | $3.9M | $2.4M | $1.2M | $599,000 | $99,000 | 0 | $1.3M | $6.2M |
| Total Assets | $35.0M | $41.3M | $150.4M | $253.9M | $358.1M | $543.0M | $756.6M | $607.1M | $742.4M |
| Accounts Payable | $5.1M | $15.6M | $19.4M | $43.5M | $61.4M | $109.3M | $125.4M | $95.1M | $124.1M |
| Short-term Debt | $3.6M | $253,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $17.8M | $30.2M | $36.2M | $77.8M | $98.8M | $159.5M | $185.9M | $168.6M | $202.4M |
| Long-term Debt | $1.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $24.3M | $30.2M | $36.2M | $87.0M | $106.2M | $166.0M | $203.2M | $185.0M | $226.4M |
| Retained Earnings | -$104.6M | -$104.9M | -$113.5M | -$68.2M | -$2.4M | $27.9M | $90.0M | $144.3M | $202.8M |
| Total Equity | $10.7M | $11.1M | $114.3M | $166.9M | $251.8M | $377.0M | $553.4M | $422.1M | $516.0M |
| Total Debt | $5.2M | $253,000 | 0 | $9.5M | $8.7M | $7.7M | $19.4M | $19.3M | $27.7M |
| Net Debt | $497,000 | $126,000 | -$80.4M | -$99.8M | -$110.8M | -$181.6M | -$351.7M | -$208.7M | -$282.4M |
| Working Capital | -$1.0M | -$5.7M | $96.3M | $112.4M | $159.7M | $274.3M | $454.5M | $304.1M | $349.4M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 2.14 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 8.86 |
Profitability
| Return on Equity | 15.98% |
| Return on Invested Capital | 15.32% |
| Return on Assets | 10.98% |
| Gross Margin | 24.57% |
| Operating Margin | 8.55% |
| Net Margin | 6.00% |
Related companies: ALVO · GDRX · OMCL · OMDA · PHR · SDGR
Explore sector: Healthcare · Medical - Healthcare Plans
More sections of PGNY: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks